Claspin Protein Identified as Key Regulator for Cell Proliferation

Researchers from the Genome Dynamics Project team at the Tokyo Metropolitan Institute of Medical Science have made a breakthrough in understanding the mechanisms controlling cellular proliferation. The team has identified a new cellular growth mechanism that sheds light on the phosphoinositide 3-kinase (PI3K) –mTOR pathway, which plays a crucial role during the preparatory stages for proliferation. The researchers also found that dysregulation of this pathway can lead to genome instability and uncontrolled growth of cancer cells.

Organisms have developed intricate stress response systems to deal with stressors. In the cellular response pathway to replication stress, a signal is transmitted from sensor kinase (ATR) to effector kinase (Chk1) to temporarily arrest the progression of replication and cell division.

Claspin mediates ATR to Chk1 signaling in the replication stress response. ATR phosphorylates Chk1 in the Claspin-Chk1 complex, and this phosphorylation requires Claspin as a mediator for the checkpoint signal transduction.

The team discovered that Claspin is essential for activating the PI3K-PDK1-mTOR pathway and downstream factors, as well as for cell survival during serum-induced growth restart. The researchers found that Claspin directly interacts with PI3K and mTOR and is required to activate PI3K-PDK1-mTOR and mTOR downstream factors, p70S6K, and 4EBP1, during the recovery from serum starvation.

The PI3K-mTOR pathway is dysregulated in several human diseases, particularly cancer, and this study provides new targets for therapeutic interventions for metabolic disorders such as obesity, diabetes, and cancer resulting from dysregulation of the mTOR pathway. The study results indicate that Claspin could be a potential target for drug development to regulate cell growth.

The scientists hope their work, published in Molecular & Cellular Biology, offers new insights into the mechanisms behind cellular proliferation and leads to new therapeutic strategies for metabolic disorders and cancer.